Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%
Cencora Has Introduced Its Full Fiscal Year 2025 Financial Guidance, Which Reflects Adjusted Operating Income Growth Of 5%-6.5% And Adjusted Diluted EPS Growth Of 8%-10%
Cencora已發佈了其2025財政年度的完整財務指引，其中調整後營業收入增長爲5%-6.5%，調整後每股攤薄後收益增長爲8%-10%
Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis
2025財年預期基於調整後（非GAAP）的基礎
- Revenue growth to be in the range of 7 to 9 percent;
- U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;
- International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent;
- Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.
- 營業收入增長區間爲7%至9%；
- 美國醫療保健解決方案部門營業收入增長區間爲7%至9%；
- 國際醫療保健解決方案部門營業收入增長區間爲7%至9%；
- 調整後的稀釋每股收益在14.80美元至15.10美元之間；
Additional expectations include:
其他預期包括：
- Adjusted operating income growth to be in the range of 5 to 6.5 percent;
- U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;
- International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent;
- Interest expense to be in the range of $150 million to $170 million;
- Adjusted effective tax rate of approximately 21 percent;
- Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion;
- Capital expenditures to be approximately $600 million; and
- Weighted average diluted shares outstanding to be approximately 196 million.
- 調整後的營業收入增長區間爲5%至6.5%；
- 美國醫療保健解決方案部門營業收入增長區間爲5%至6.5%；
- 國際醫療解決方案部門營業收入增長率將在5％至6.5％的區間內；
- 利息費用將在15000萬至17000萬美元的區間內；
- 調整後的有效稅率約爲21％；
- 調整後的自由現金流將在20億至30億美元的區間內；
- 資本支出約爲60000萬美元；並且
- 加權平均攤薄股份約爲19600萬。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間